5-HT1A激动剂治疗帕金森病左旋多巴诱导的运动障碍。

IF 2.3 Q3 CLINICAL NEUROLOGY Neurodegenerative disease management Pub Date : 2023-04-01 DOI:10.2217/nmt-2022-0039
Jawad Al-Kassmy, Christine Sun, Philippe Huot
{"title":"5-HT1A激动剂治疗帕金森病左旋多巴诱导的运动障碍。","authors":"Jawad Al-Kassmy,&nbsp;Christine Sun,&nbsp;Philippe Huot","doi":"10.2217/nmt-2022-0039","DOIUrl":null,"url":null,"abstract":"<p><p>Levodopa is the most effective agent for treating the symptoms of Parkinson's disease (PD). However, levodopa-induced dyskinesia remains a significant complication that manifests after few years of treatment, for which therapeutic options remain limited. Several agonists of the serotonin type 1A (5-HT<sub>1A</sub>) receptor with varying levels of efficacy and interaction at other sites, have been tested in the clinic. Clinical trials testing 5-HT<sub>1A</sub> agonists have yielded inconsistent results in alleviating dyskinesia, especially that the antidyskinetic benefit observed was often accompanied by an adverse effect on motor function. In this article, we summarize and analyze the various clinical trials performed with 5-HT<sub>1A</sub> agonists in PD patients with dyskinesia and offer perspectives on the future of this class of agents in PD.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"5-HT<sub>1A</sub> agonists for levodopa-induced dyskinesia in Parkinson's disease.\",\"authors\":\"Jawad Al-Kassmy,&nbsp;Christine Sun,&nbsp;Philippe Huot\",\"doi\":\"10.2217/nmt-2022-0039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Levodopa is the most effective agent for treating the symptoms of Parkinson's disease (PD). However, levodopa-induced dyskinesia remains a significant complication that manifests after few years of treatment, for which therapeutic options remain limited. Several agonists of the serotonin type 1A (5-HT<sub>1A</sub>) receptor with varying levels of efficacy and interaction at other sites, have been tested in the clinic. Clinical trials testing 5-HT<sub>1A</sub> agonists have yielded inconsistent results in alleviating dyskinesia, especially that the antidyskinetic benefit observed was often accompanied by an adverse effect on motor function. In this article, we summarize and analyze the various clinical trials performed with 5-HT<sub>1A</sub> agonists in PD patients with dyskinesia and offer perspectives on the future of this class of agents in PD.</p>\",\"PeriodicalId\":19114,\"journal\":{\"name\":\"Neurodegenerative disease management\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurodegenerative disease management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/nmt-2022-0039\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nmt-2022-0039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

左旋多巴是治疗帕金森病(PD)症状最有效的药物。然而,左旋多巴诱导的运动障碍仍然是一个重要的并发症,在治疗几年后表现出来,治疗选择仍然有限。几种5-羟色胺1A (5-HT1A)受体激动剂具有不同程度的疗效和在其他部位的相互作用,已经在临床中进行了测试。测试5-HT1A激动剂的临床试验在缓解运动障碍方面得出了不一致的结果,特别是观察到的抗运动障碍益处往往伴随着对运动功能的不利影响。在这篇文章中,我们总结和分析了5-HT1A激动剂在帕金森病患者运动障碍中的各种临床试验,并对这类药物在帕金森病患者中的未来发展提出了展望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
5-HT1A agonists for levodopa-induced dyskinesia in Parkinson's disease.

Levodopa is the most effective agent for treating the symptoms of Parkinson's disease (PD). However, levodopa-induced dyskinesia remains a significant complication that manifests after few years of treatment, for which therapeutic options remain limited. Several agonists of the serotonin type 1A (5-HT1A) receptor with varying levels of efficacy and interaction at other sites, have been tested in the clinic. Clinical trials testing 5-HT1A agonists have yielded inconsistent results in alleviating dyskinesia, especially that the antidyskinetic benefit observed was often accompanied by an adverse effect on motor function. In this article, we summarize and analyze the various clinical trials performed with 5-HT1A agonists in PD patients with dyskinesia and offer perspectives on the future of this class of agents in PD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
35
期刊最新文献
Amyloid-related imaging abnormalities (ARIA) and their radiological, biological and clinical characteristics: a plain language summary Effects and mechanisms of computerized cognitive training in Huntington's disease: protocol for a pilot study Medicinal cannabis in neurodegenerative disorders: an open label, dose finding, safety and efficacy study. Glycine and clozapine: potential relevance for the treatment of Parkinson's disease. Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1